```
가
                    82
    82
                               47 (57.3%)
                                                                     7
    19 (
                                       21
                                                                     35
         18 ,
                                        17
                           2
       5
                                           6 - 15 mm(
                                                         9.5 mm)
                         14
                                       3 ,
                                                           2
                                                                           6.5 -
10.7 mm(
             8.2 mm)
                                                    19,
                                5.5 - 9.2 mm(
                                                 6.8 mm)
                16
                                           가
(p=0.002).
                 가 6 mm
                                                                    7 mm
                                                                      82.5%,
    82.6%,
                 82.4%,
                                  76%,
                                                 87.5%
                                                                        7 mm
  87.8%,
               95.7%,
                            77.1%,
                                             84.9%,
                                                              93.1%
```

: Uterus, endometrium. Uterus, US. Uterine neoplasms, US. Ovary, abnormalities. Ovary, cysts.

```
: 2004 2 19 , : 2004 3 30 , : 2004 4 10 , : 2004 5 15 

: , (443 - 721) 5, , 

Tel. (031)219 - 5856 Fax. (031)219 - 5862 E - mail: ejlee@ajou.ac.kr
```

```
23
                                                                        2004
                                                               8
                                                                                          59,
                                                                             15
                          , 가
                                        4 - 10%
                                                                    (disordered proliferative endometrium)
                                                                             Ultramark - 9 HDI (Advanced Technology
                                                            Laboratories, Bothell, Washington), 5 MHz
                         [1-5].
                                                            Sequoia(Acuson, Mountain View, CA), 4-8 MHz
                                       1949
                                                               8 - French
                                                    [1-
4, 6-11].
  4 - 5%가 40
                                                                                  10 - 15 ml
                                                                                                                20 -
                                             unopposed
                                                            30
estrogen
                                                              2
                                                                                 가
                        가
                                    가
                                                 가
                                     가
                                              [3, 8, 12 -
14].
                           가
                                                                                                   가
                                                                                                   가
                                                                                 5 mm
                                                                                                                [21].
                         가
                                 [15 - 19],
                                                                              (diffuse),
                                                                                              (focal),
                                                                                                           (uniform),
                                                                  (polypoid)
                                                                              SPSS 10.0(Statistical Package for Social
       8
                                                            Sciences; SPSS Inc., Chicago, IL)
                (12)
  (70)
                                     82
                                                                                                 Student - t test
                    18 - 41 (
                                   30.9 )
                                                            ANOVA (analysis of variance) test
                                                                            ROC(receiver operating characteri - stic)
                                                                      가
                                    (65),
           , 10
                                                            standard)
           가
                                    (35),
                 (luteinizing hormone),
                 (prolactin),
                   가,
                                  (progesterone)
          (follicular stimulating hormone)
   (34) [1-2, 4-5].
 가 7 mm
                                                                   82
                                                                                (57.3\%)
```

[6].

8 mm

14

7 (8.5%)

),

1(

IA가 5 , IB가 2 I(well differentiated) 5 5-7 cm 2 7 5 6-8 mm , 3 (hyperthecosis) 19 (23.2%)(6.1%)2, 3.4 cm 가 . 35 21 (25.6%)18 (22%), 6 17 (20.7%) (Fig. 1). 3





Fig. 1. Endometrial carcinoma in a 38-year-old woman with polycystic ovarian disease.

A, B. Sagittal and transverse sonohysterogram show a diffuse polypoid endometrial thickening (8.4 mm in maximal thickness) with irregular surface and disruption of endometrial-myometrial interface in the anterior corpus (arrows). The endometrial cavity is poorly distended during saline infusion and obliterated by tumor and adhesions.

C, D. Photography of the resected uterus reveals multiple papillary protruding endometrial masses involving the entire endometrial surface. Histologic findings suggested a well-differentiated endometrioid adenocarcinoma with associated endometrial hyperplasia and superficial myometrial invasion (arrow). Both ovaries are markedly enlarged, each measuring 6.5×5 cm and 5×4 cm, and show multiple small subcapsular cystic follicles and irregular thickened, sclerotic cortical tissue.








Fig. 2. Endometrial hyperplasia in a 30-year-old woman with polycystic ovarian disease. **A, B.** Sagittal and transverse sonohysterogram show a diffuse uniform endometrial thickening measuring 9.2 mm with a homogeneous hyperechogenicity and smooth surface. The uterine cavity is well distended and the endometrial-myometrial interface is preserved.




Fig. 3. Atypical hyperplasia in a 28-year-old woman with polycystic ovarian disease. **A, B.** Sagittal and transverse sonohysterogram show a diffuse polypoid endometrial thickening (7.4 mm in maximal thickness) with an irregular surface and a poorly distended endometrial cavity.




Fig. 4. Endometrial polyps in a 22-year-old woman with polycystic ovarian disease. **A, B.** Sagittal and transverse sonohysterogram show 1.0 and 0.9 cm polypoid endometrial masses (arrows) with smooth surface in the anterior and posterior corpus




Fig. 5. Disordered proliferative endometrium in a 25-year-old woman with polycystic ovarian disease.

A, B. Sagittal and transverse sonohysterogram show a diffuse uniform endometrial thickening (6.4 mm in maximal thickness) with a smooth surface and homogeneous echogenicity.

Table 1. Endometrial Thickness at Sonohysterography in Patients with Polycystic Ovarian Disease

Pathologic diagnosis	Endometrial thickness (mm)								
	<5	5 - 6	6 - 7	7 - 8	8 - 9	9 - 10	10 - 11	11	Range (Mean)
E carcinoma (n=7)			1	1	2	1		2	6 - 15 (9.5)
E hyperplasia (n=16)			3	3	6	3	1		6.5 - 10.7 (8.2)
DPE (n=17)		4	7	3	1	2			5.5 - 9.2 (6.8)
Normal E (n=17)	13	3	1						2.2 - 6.7 (4.3)

E: Endometrium, DPE: Disordered proliferative endometrium

가 6 mm 100% 7 mm 82.5%, 82.6%, 82.4%, 76%, 87.5% 7 13 가 7 mm 6 16 3 (1 7 mm 1) 17 6 가 7 mm 11 17 7 mm 7 mm

, [1 - 4, 6 - 11]. 가

unopposed estrogen (mitogenic effect)

Table 2. Diagnostic Accuracy of Sonohysterography for Predicting Endometrial Abnormalities in 82 Patients with Polycystic Ovarian Disease

C	Pathologic diagnosis					
Sonohysterographic diagnosis	Abnormal	Normal	Total			
Abnormal	45	8	53			
Normal	2	27	29			
Total	47	35	82			

(overexpression) [1, 2, 10], , , ,

estrogen - producing aromatase
estrogen 7 [3 - 5].

가 , , , 가 가 . 가 , 가 , [1, 2, 4].

. 35 25%가 , 35.7% , 25% 가 [6-9], . 0.4%,

18%, 23 - 25% [6, 10], 30%

[11].

, ,

26.3% , [2, 3], 가 8.2 mm triple - line appearance가 [6]. , 5 mm 5 - 15 mm(7.5 mm) 64.3% [1-3, 6, 9], 가 5 - 11 mm 87.2% 10 mm 15 mm , 35.9% (asynchronization) [6]. [2, 3]. 가 7-15 22% 20.7% 9.5 mm) 7.7 mm) mm(5 - 14 mm(6.8 mm 가 6 mm 가 7 mm 가 7 7 - 15 mm mm가 가 [2, 3, 6]. 가 6 mm 62.2% , 7 mm 76%, 8 mm 83.3% 가 6 mm 7 mm , 6 mm 5-6 mm 4 -7 mm [6]. 6 mm [15]. 10 - 12 mm [20 - 23]. 가 가 [16-19, 20, 23]. 5-6 mm 가 1. Balen A. Polycystic ovary syndrome and cancer. Hum Reprod Update 2001;7:522-525 2. Balen AH, Conway GS, Kaltsas G, et al. Polycystic ovary syn-57.3% drome: the spectrum of the disorder in 1741 patients. Hum Reprod 25.6% 가 1995;10:2107-2111 8.5% 3. Elliott JL, Hosford SL, Demopoulos RI, Perloe M, Sills ES.

531

Endometrial adenocarcinoma and polycystic ovary syndrome: risk factors, management, and prognosis. South Med J 2001;94:529-

9.5 mm

23.2%

- Hardiman P, Pillay OC, Atiomo W. Polycystic ovary syndrome and endometrial carcinoma. Lancet 2003;361:1810-1812
- American College of Obstetricians and Gynecologists. ACOG practice bulletin. Polycystic ovary syndrome. Obstet Gynecol 2002;100:1389-1402
- Cheung AP. Ultrasound and menstrual history in predicting endometrial hyperplasia in polycystic ovary syndrome. Obstet Gynecol 2001;98:325-331
- 7. Chamlian DL, Taylor HB. Endometrial hyperplasia in young women. Obstet Gynecol 1970;36:659-666
- Gregorini SD, Lespi PJ, Alvarez GR. Endometrial carcinoma with polycystic ovaries. Report of two cases in women younger than 40 years old. Medicina 1997;57:209-212
- Sindi O, Saleh A, Rouzi AA. Diagnosis of simple endometrial hyperplasia in a woman with polycystic ovary syndrome with use of hysterosalpingography. Fert Steril 2002;77:1069-1070
- 10. Kurabayashi T, Kase H, Suzuki M, Sugaya S, Fujita K, Tanaka K. Endometrial abnormalities in infertile women. J Reprod Med 2003;48:455-459
- 11. Karabakhtsian R, Heller DS, Singhal P, Sama J. Malignant mixed mesodermal tumor in a young woman with polycystic ovary syndrome: a case report. J Reprod Med 2002;47:946-948
- Crissman JD, Azoury RS, Barnes AE, Schellhas HF. Endometrial carcinoma in women 40 years of age or younger. Obstet Gynecol 1981:57:699-704
- Gallup DG, Stock RJ. Adenocarcinoma of the endometrium in women 40 years of age or younger. Obstet Gynecol 1984;64:417-420
- 14. Jafari K, Javaheri G, Ruiz G. Endometrial adenocarcinoma and the Stein-Leventhal syndrome. Obstet Gynecol 1978;51:97-100
- 15. Karlsson B, Granberg S, Wikland M, et al. Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding- a Nordic multicenter study. Am J Obstet Gynecol

- 1995;172:1488-1494
- 16. Lindheim SR, Adsuar N, Kushner DM, Pritts EA, Olive DL. Sonohysterography: a valuable tool in evaluating the female pelvis. Obstet Gynecol Surv 2003;58:770-784
- 17. Soares SR, Barbosa dos Reis MM, Camargos AF. Diagnostic accuracy of sonohysterography, transvaginal sonography, and hysterosalpingography in patients with uterine cavity diseases. Fertil Steril 2000;73:406-411
- 18. Strandell A, Bourne T, Bergh C, Granberg S, Asztely M, Thorburn J. The assessment of endometrial pathology and tubal patency: a comparison between the use of ultrasonography and X-ray hysterosalpingography for the investigation of infertility patients. Ultrasound Obstet Gynecol 1999;14:200-204
- 19. Alatas C, Aksoy E, Akarsu C, Yakin K, Aksoy S, Hayran M. Evaluation of intrauterine abnormalities in infertile patients by sonohysterography. Hum Reprod 1997;12:487-490
- 20. Farquhar C, Ekeroma A, Furness S, Arroll B. A systematic review of transvaginal ultrasonography, sonohysterography and hysteroscopy for the investigation of abnormal uterine bleeding in premenopausal women. Acta Obstet Gynecol Scand 2003;82:493-504
- 21. Dijkhuizen FP, Brolmann HA, Potters AE, Bongers MY, Heintz AP. The accuracy of transvaginal ultrasonography in the diagnosis of endometrial abnormalities. Obstet Gynecol 1996;87:345-349
- 22. Dijkhuizen FP, De Vries LD, Mol BW, et al. Comparison of transvaginal ultrasonography and saline infusion sonography for the detection of intracavitary abnormalities in premenopausal women. Ultrasound Obstet Gynecol 2000;15:371-372
- 23. Dueholm M, Forman A, Jensen ML, Laursen H, Kracht P. Transvaginal sonography combined with saline contrast sonohysterography in evaluating the uterine cavity in premenopausal patients with abnormal uterine bleeding. Ultrasound Obstet Gynecol 2001;18:54-61

= Abstract =

Sonohysterographic Findings of Endometrial Abnormalities in Women with Polycystic Ovarian Disease

Eun Ju Lee, M.D.

Department of Diagnostic Radiology, Ajou University, School of Medicine

PURPOSE: To describe the sonohysterographic findings of endometrial abnormalities, and to determine the usefulness of sonohysterography (SH) for predicting endometrial abnormalities in women with polycystic ovarian disease (PCOD).

MATERIALS and METHODS: 82 patients with PCOD who had vaginal bleeding or endometrial thickening and lesion mass on baseline transvaginal sonography were prospectively examined with SH. The SH findings were evaluated for endometrial thickness, the presence of endometrial thickening and lesion mass, echogenicity and surface contour, distensibility of the endometrial cavity, and disruption of endometrial-myometrial interface. These findings were compared with the pathologic findings and the diagnostic accuracy of SH for predicting endometrial abnormalities was assessed.

RESULTS: Endometrial abnormalities were identified in 47 (57.3%) of 82 PCOD patients, and their pathologic diagnosis included endometrial carcinoma in 7 cases, hyperplasia in 19 cases (atypical hyperplasia, n=5), and polyp in 21 cases. Of the 35 patients who did not have endometrial abnormalities, there was disordered proliferative endometrium in 18 cases and normal proliferative or secretory endometrium in 17 cases. The SH findings of endometrial carcinoma were endometrial thickening in 5 cases, endometrial thickening and lesion mass in 2 cases, and the endometrial thickness ranged from 6 mm to 15 mm (mean 9.5 mm). They were characterized as a diffuse polypoid endometrial thickening or a sessile endometrial mass with irregular surface, homogeneous hyperechogenicity, and obliteration of the endometrial cavity. Endometrial hyperplasia appeared as endometrial thickening in 14 cases, endometrial lesion mass in 3 cases, and endometrial thickening and lesion mass in 2 cases, and the endometrial thickness was between 6.5 - 10.7 mm (mean 8.2 mm). They showed a diffuse uniform endometrial thickening or a polypoid endometrial lesion mass with homogeneous hyperechogenicity and a regular surface. Endometrial polyps appeared as endometrial mass in 19 cases, and focal endometrial thickening and endometrial thickening and lesion mass occurred in one case each, respectively. They had a homogeneously echogenic, polypoid endometrial mass with a regular surface. 16 cases with disordered proliferative endometrium had endometrial thickening, measuring between 5.5 to 9.2 mm (mean 6.8 mm) in thickness, which were homogeneously hyperechoic and smooth surfaced, and one case each had an endometrial mass and an endometrial thickening with mass. The endometrial thickness of endometrial carcinoma and hyperplasia was significantly higher than those of disordered proliferative endometrium (p=0.002). Endometrial abnormalities could be excluded when the endometrial thickness was less than 6 mm. An endometrial thickness of 7 mm or greater was most useful parameter for the differentiation of endometrial carcinoma and hyperplasia from disordered proliferative endometrium with a sensitivity of 82.6%, a specificity of 82.4%, an accuracy of 82.5%, a positive predictive value of 76%, and a negative predictive value of 87.5%. Using endometrial thickening greater than 7 mm and the abnormal findings as the positive findings for predicting endometrial abnormalities in PCOD patients, the sensitivity, specificity, accuracy, positive predictive value, and negative predictive value of SH were 95.7%, 77.1%, 87.8%, 84.9%, and 93.1%, respectively.

CONCLUSION: The SH findings were accurate and could be useful for predicting endometrial abnormalities for women with PCOD.

Address for reprints: Eun Ju Lee, M.D., Department of Diagnostic Radiology, Ajou University, School of Medicine San 5, Woncheon-dong, Yeongtong-gu, Suwon-si, Gyeonggi-do 443-721, Korea.

Tel. 82-31-219-5856 Fax. 82-31-219-5862 E-mail: ejlee@ajou.ac.kr